Nature Communications (Sep 2018)
LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L
- Lucia Taraborrelli,
- Nieves Peltzer,
- Antonella Montinaro,
- Sebastian Kupka,
- Eva Rieser,
- Torsten Hartwig,
- Aida Sarr,
- Maurice Darding,
- Peter Draber,
- Tobias L. Haas,
- Ayse Akarca,
- Teresa Marafioti,
- Manolis Pasparakis,
- John Bertin,
- Peter J. Gough,
- Philippe Bouillet,
- Andreas Strasser,
- Martin Leverkus,
- John Silke,
- Henning Walczak
Affiliations
- Lucia Taraborrelli
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- Nieves Peltzer
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- Antonella Montinaro
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- Sebastian Kupka
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- Eva Rieser
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- Torsten Hartwig
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- Aida Sarr
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- Maurice Darding
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- Peter Draber
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- Tobias L. Haas
- Institute of General Pathology, Università Cattolica del Sacro Cuore
- Ayse Akarca
- Department of Cellular Pathology, University College London
- Teresa Marafioti
- Department of Cellular Pathology, University College London
- Manolis Pasparakis
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), and Center for Molecular Medicine (CMMC), University of Cologne
- John Bertin
- Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline
- Peter J. Gough
- Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline
- Philippe Bouillet
- The Walter and Eliza Hall Institute of Medical Research
- Andreas Strasser
- The Walter and Eliza Hall Institute of Medical Research
- Martin Leverkus
- Department of Dermatology & Allergology, University Hospital of RWTH Aachen University
- John Silke
- The Walter and Eliza Hall Institute of Medical Research
- Henning Walczak
- Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London
- DOI
- https://doi.org/10.1038/s41467-018-06155-8
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 12
Abstract
TNF mediated inflammation is critical in autoimmune mediated pathology, however many patients are refractory to current anti-TNF therapeutics. Here the authors show induction of several death ligands, in addition to TNF is sufficient to cause fatal dermatitis in a LUBAC deficient murine model of disease.
